4//SEC Filing
Besthof Robert 4
Accession 0000950142-21-001936
CIK 0001719406other
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 6:44 PM ET
Size
8.5 KB
Accession
0000950142-21-001936
Insider Transaction Report
Form 4
Besthof Robert
Chief Comm. & Patient Officer
Transactions
- Award
Employee Stock Option (Right to buy)
2021-05-24+347,200→ 347,200 totalExercise: $3.08Exp: 2030-10-23→ Common Stock (347,200 underlying) - Award
Employee Stock Option (Right to buy)
2021-05-24+347,200→ 347,200 totalExercise: $0.21Exp: 2026-03-01→ Common Stock (347,200 underlying)
Footnotes (2)
- [F1]Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement).
- [F2]Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25.
Documents
Issuer
NRX Pharmaceuticals, Inc.
CIK 0001719406
Entity typeother
Related Parties
1- filerCIK 0001864650
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 6:44 PM ET
- Size
- 8.5 KB